AASLD: Peg-Interferon and Ifn-Ribavirin Combo Keep HCV in Check Long Term
16th Nov 2005, 18:57 GMT
SAN FRANCISCO - Pegylated interferon alfa-2a alone or in combination with ribavirin (Copegus) produces sustained virologic responses (SVR) for at least five years in patients treated for hepatitis C infection.
AASLD: Peg-Interferon and Ifn-Ribavirin Combo Keep HCV in Check Long Term related news:
- AASLD: Consensus Interferon Plus Ribavirin Gives HCV Patients Second Chance — MedPage Today Infectious Disease
- Tumor Necrosis Factor-[alpha] Promoter Polymorphism at Position -308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection — J Infect Dis Latest Articles
- Volume 41, number 12: Spontaneous Hepatic Decompensation in Patients Coinfected with HIV and Hepatitis C Virus during Interferon-Ribavirin Combination Treatment — Clin Infect Dis Latest Issue
- AASLD: Schizophrenics and Drug Abusers Get Short Shrift in HCV Therapy — MedPage Today Gastroenterology
- Intarcia Therapeutics Announces Interim Results From a Phase 2 Study of Omega Interferon in HCV — Bio-Technology News from StratCenter.com
- AASLD: Weight-Based Dosing of Rebetol Improves Outlook for HCV — MedPage Today Gastroenterology
- NewYork-Presbyterian/Weill Cornell: Largest Hepatitis C Trial in U.S. Patients Shows Weight-Based REBETOL in Combination With PEG-INTRON Increases Sustained Response, Lowers Relapse — Market Wire - Pharmaceuticals and Biotech
- Largest hepatitis-C U.S. study defines optimal therapy — News-Medical News Feed
- AASLD: Protease Inhibitors Open New Front on HCV — MedPage Today.com Latest Headlines
- Hepatitis treatment studies' results announced — OnMedica Latest News